Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 17/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | OXTR | P30559 | 1/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20641623 | 0.86 | NAMPT (0.53) | NAMPTCYP2C9 | |
| SCHEMBL27431471 | 0.86 | NAMPT (0.53) | NAMPTCYP2C9 | |
| SCHEMBL22797245 | 0.81 | EHMT2 (0.47) | OXTRAVPR1A | |
| SCHEMBL23558620 | 0.78 | NAMPT (0.53) | NAMPTPRMT5 | |
| SCHEMBL22797475 | 0.78 | CHRM4 (0.34) | NAMPT | |
| SCHEMBL22797253 | 0.78 | PTPN2 (0.46) | OXTRAVPR1A | |
| SCHEMBL5403405 | 0.77 | KDM4E (0.54) | JAK2JAK1PRMT5 | |
| SCHEMBL20936864 | 0.75 | NR1H2 (0.51) | NAMPTJAK2JAK1PRMT5 | |
| SCHEMBL29501504 | 0.75 | NR1H2 (0.51) | NAMPTJAK2JAK1PRMT5 | |
| SCHEMBL23545080 | 0.75 | NR1H2 (0.51) | NAMPTJAK2JAK1PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11325896-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2022-05-10 | — | — | US | disclosed |
| US-11325896-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2022-05-10 | — | — | US | disclosed |
| US-20200392117-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392117-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM2, CHRM3, CHRM4 | NAMPT 2015/4885CYP2C9 2471/4885OXTR 236/4885 |
| US-11325896-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | CHRM2, CHRM3, CHRM5 | NAMPT 2237/4885CYP2C9 1943/4885OXTR 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.